FDA Drug Information Update on Guardian Pharmacy's Compounded Triamicinolone and Moxifloxacin Product for Intravitreal Injection

PUBLISHED: Jul 28, 2017
Relevant to: Ambulatory Care, Critical Access Hospitals, Hospitals, Medical Office/Clinic

The U.S. Food and Drug Administration (FDA) received adverse event reports on April 5 and June 1, 2017, and conducted follow-up, concerning at least 43 patients who were administered intravitreal (eye) injections of a drug containing triamcinolone (steroid) and moxifloxacin (anti-infective) compounded by Guardian Pharmacy Services in Dallas, Texas. The patients were administered Guardian’s product at the end of a cataract surgery procedure at the PRG Dallas Ambulatory Surgery Center in Dallas, Texas, by physicians affiliated with the Key Whitman Eye Center, and at the Park Central Surgical Center in Dallas, Texas, by physicians affiliated with Tylock-George Eye Care.

According to information received from Park Central, Guardian’s product was injected into the vitreous of the eye at the end of the cataract surgery procedure. The purpose of the injection was to provide post-operative prophylaxis for ocular inflammation and endophthalmitis with the expectation that the patient would not need to use post-operative eye drops. Over the course of several months, patients developed various symptoms, including vision impairment (blurred or decreased vision), poor night vision, loss of color perception, photophobia (light sensitivity), glare, halos, flashing lights, ocular discomfort, pain, loss of balance, headaches, and/or nausea. A number of the symptoms were not exhibited until at least one month postoperatively.

During follow-up examinations of the Park Central patients, physicians observed that the patients had diminished visual function involving both visual acuity and visual fields. Optical coherence tomography testing initially showed macular edema (swelling), which was followed in some cases by retinal degeneration. While the symptoms reportedly improved in some patients over the five-month post-operative period, a number of patients remain with a significant reduction in best-corrected visual acuity and visual fields.

Compounded drugs have not been reviewed by FDA for safety, effectiveness, and quality. Although compounded drugs can serve an important medical need for certain patients, they also present risks to patients.

Follow the link below for additional information.

Want to read the full alert and receive alert emails?

Browse Additional Alerts